Gilead Sciences Acquires MiroBio

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Pharmaceuticals

Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.

Moderna Acquires OriCiro Genomics K.K. for $85 Million

January 5, 2023

Biotechnology

Moderna has entered into a definitive agreement to acquire OriCiro Genomics K.K. for $85 million. The deal is intended to add cell-free DNA synthesis and amplification technologies that complement Moderna’s mRNA manufacturing expertise and accelerate its R&D.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

Gilead Sciences Acquires Forty Seven for $4.9 Billion

March 2, 2020

Biotechnology

Gilead Sciences agreed to acquire clinical-stage immuno-oncology company Forty Seven for $95.50 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition adds Forty Seven's lead investigational antibody magrolimab to Gilead's oncology pipeline and is expected to close in Q2 2020 subject to customary approvals.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.